A phase II study of Docetaxel with Bevacizumab for previously treated non-squamous non-small cell lung cancer. - A phase II study of Docetaxel with Bevacizumab for previously treated non-squamous non-small cell lung cancer.

First Department of Internal Medicine,0 个研究点目标入组 25 人开始时间: 2012年8月20日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Prior treatment with Docetaxel. 2. History or complication of hemoptysis with 2.5mL per time or more. 3.Patients with lesions at risk of causing hemoptysis in hilar by chest CT. 4. Invasion to major vessel of tumor. 5. Interstitial pneumonia or pulmonary fibrosis detectable on X ray. 6.Have uncontrolled effusion (Pleural, peritoneal effusion, or cardiac effusion which requires drainage for symptom management). 7. Planning of concurrent thoracic radiotherapy (including if radiation field does not cover the chest). 8. Have active CNS metastases. 9. Have another active malignancy. 10. Major surgery within 4wks prior to the study. 11. Urinary protein <= 2+ 12. Patients with therapeutic anticoagulopathy. 13. Have a history of serious systemic disease. 14. In pregnancy, during breast feeding, or possibility of pregnancy. 15. With a history of serious drug sensitivity. 16. Mental disease or psychotic manifestation. 17. Severe infection such as having a HCV Ab positive or HbsAg positive. 18. Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator.

发起方

First Department of Internal Medicine,